2/3
01:33 pm
atra
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
1/29
10:00 am
atra
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
1/27
12:47 pm
atra
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
1/22
10:00 am
atra
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
1/20
01:13 pm
atra
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
1/13
03:57 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) was given a new $6.00 price target on by analysts at New Street Research.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) was given a new $6.00 price target on by analysts at New Street Research.
1/13
10:58 am
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "hold" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $6.00 price target on the stock.
High
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "hold" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $6.00 price target on the stock.
12/19
08:44 am
atra
Atara Biotherapeutics (NASDAQ:ATRA) was given a new $25.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Atara Biotherapeutics (NASDAQ:ATRA) was given a new $25.00 price target on by analysts at Canaccord Genuity Group Inc..
11/30
08:52 am
atra
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
High
Report
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
11/14
01:10 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.